Details of the Drug

General Information of Drug (ID: DMBS632)

Drug Name

Buspirone

Synonyms

Ansial; Ansiced; Anxiron; Axoren; Bespar; Buspirona; Buspironum; Buspisal; Ansial (TN); Ansiced (TN); Anxiron (TN); Axoren (TN); Bespar (TN); BuSpar (TN); Buspimen (TN); Buspinol (TN); Buspiron (TN); Buspirona [INN-Spanish]; Buspirone (INN); Buspirone [INN:BAN]; Buspirone-MDTS; Buspironum [INN-Latin]; Buspisal (TN); Gen-Buspirone; Narol (TN); Sorbon (TN); Spamilan (TN); Spitomin (TN); Gen-Buspirone (TN); MJ-9022-1; N-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-1-cyclopentanediacetamide; 8-(4-(4-(2-Pyrimidinyl)-1-piperizinyl)butyl)-8-azaspiro(4,5)decane-7,9-dione; 8-[4-(4-Pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5]decane-7,9-dione; 8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione; 8-{4-[4-(pyrimidin-2-yl)piperazin-1-yl]butyl}-8-azaspiro[4.5]decane-7,9-dione

Indication

Disease Entry	ICD 11	Status	REF
Anxiety disorder	6B00-6B0Z	Approved	[1], [2]

Therapeutic Class

Antianxiety Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

385.5

Topological Polar Surface Area (xlogp)

2.6

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 3-4 h [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Bioavailability: The bioavailability of drug is 100% [3]
Clearance: The sytemic clearance of drug is 1.7 L/h/kg [5]
Elimination: A single-dose pharmacokinetic studies using 14C-labeled buspirone demonstrated that about 29-63% of the dose administered was excreted in the urine within 24 hours, primarily in the form of metabolites [6]
Half-life: The concentration or amount of drug in body reduced by one-half in 2 - 3 hours [6]
Metabolism: The drug is metabolized via the hepatic [6]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 2.59394 micromolar/kg/day [7]
Vd: The volume of distribution (Vd) of drug is 5.3 L/kg [5]
Water Solubility: The ability of drug to dissolve in water is measured as 0.0214 mg/mL [4]

Chemical Identifiers

Formula: C21H31N5O2
IUPAC Name: 8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione
Canonical SMILES: C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4
InChI: InChI=1S/C21H31N5O2/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20/h5,8-9H,1-4,6-7,10-17H2
InChIKey: QWCRAEMEVRGPNT-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 2477
ChEBI ID: CHEBI:3223
CAS Number: 36505-84-7
DrugBank ID: DB00490
TTD ID: D0U2OO
VARIDT ID: DR00683
INTEDE ID: DR0248
ACDINA ID: D00084

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 1A receptor (HTR1A)	TTSQIFT	5HT1A_HUMAN	Agonist	[8]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[9]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[10]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[10]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[11]
Cytochrome P450 102A1 (cyp102)	DE4OGUF	CPXB_BACMB	Substrate	[12], [13]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Anxiety disorder

ICD Disease Classification

6B00-6B0Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
5-HT 1A receptor (HTR1A)	DTT	HTR1A	2.18E-01	-0.11	-0.51
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	5.16E-01	4.53E-02	3.54E-01
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	2.06E-01	-1.87E-01	-6.20E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	3.40E-01	1.04E-01	7.11E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	7.43E-01	2.19E-03	1.72E-02
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	3.18E-03	2.30E-01	2.71E+00
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	8.32E-01	4.74E-02	1.73E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Buspirone

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Methylphenobarbital	DMDSWAG	Moderate	Increased metabolism of Buspirone caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[55]
-----------

Coadministration of a Drug Treating the Disease Different from Buspirone (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Major	Additive serotonergic effects by the combination of Buspirone and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[56]
Metreleptin	DM1NOEK	Moderate	Increased metabolism of Buspirone caused by Metreleptin mediated induction of CYP450 enzyme.	Acute diabete complication [5A2Y]	[55]
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Buspirone caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[55]
Arn-509	DMT81LZ	Major	Increased metabolism of Buspirone caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[55]
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Buspirone and Oliceridine.	Acute pain [MG31]	[57]
Mitotane	DMU1GX0	Major	Increased metabolism of Buspirone caused by Mitotane mediated induction of CYP450 enzyme.	Adrenal cancer [2D11]	[55]
Voriconazole	DMAOL2S	Moderate	Decreased metabolism of Buspirone caused by Voriconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[58]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Buspirone caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[59]
Desipramine	DMT2FDC	Major	Additive serotonergic effects by the combination of Buspirone and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[60]
Oritavancin	DM28D05	Moderate	Increased metabolism of Buspirone caused by Oritavancin mediated induction of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[55]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Buspirone caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[58]
Linezolid	DMGFPU2	Major	Additive serotonergic effects by the combination of Buspirone and Linezolid.	Bacterial infection [1A00-1C4Z]	[61]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Buspirone caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[55]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Buspirone caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[62]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Buspirone caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[63]
Phenylbutazone	DMAYL0T	Moderate	Increased metabolism of Buspirone caused by Phenylbutazone mediated induction of CYP450 enzyme.	Chronic pain [MG30]	[55]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Buspirone and Dihydrocodeine.	Chronic pain [MG30]	[64]
Levomilnacipran	DMV26S8	Major	Additive serotonergic effects by the combination of Buspirone and Levomilnacipran.	Chronic pain [MG30]	[60]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Buspirone and Olopatadine.	Conjunctiva disorder [9A60]	[65]
Propofol	DMB4OLE	Moderate	Additive CNS depression effects by the combination of Buspirone and Propofol.	Corneal disease [9A76-9A78]	[66]
Alfentanil	DMVO0UB	Major	Additive serotonergic effects by the combination of Buspirone and Alfentanil.	Corneal disease [9A76-9A78]	[67]
Remifentanil	DMZTXCH	Major	Additive serotonergic effects by the combination of Buspirone and Remifentanil.	Corneal disease [9A76-9A78]	[67]
Mifepristone	DMGZQEF	Moderate	Decreased metabolism of Buspirone caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[58]
Lumacaftor	DMCLWDJ	Major	Increased metabolism of Buspirone caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[55]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Buspirone caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[68]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Buspirone and Ethanol.	Cystitis [GC00]	[65]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Buspirone caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[69]
Aprepitant	DM053KT	Moderate	Decreased metabolism of Buspirone caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[70]
Trimipramine	DM1SC8M	Major	Additive serotonergic effects by the combination of Buspirone and Trimipramine.	Depression [6A70-6A7Z]	[60]
Cyclobenzaprine	DM1YBRM	Major	Additive serotonergic effects by the combination of Buspirone and Cyclobenzaprine.	Depression [6A70-6A7Z]	[60]
Nortriptyline	DM4KDYJ	Major	Additive serotonergic effects by the combination of Buspirone and Nortriptyline.	Depression [6A70-6A7Z]	[60]
Vilazodone	DM4LECQ	Major	Additive serotonergic effects by the combination of Buspirone and Vilazodone.	Depression [6A70-6A7Z]	[60]
Paroxetine	DM5PVQE	Major	Additive serotonergic effects by the combination of Buspirone and Paroxetine.	Depression [6A70-6A7Z]	[60]
Selegiline	DM6034S	Major	Additive serotonergic effects by the combination of Buspirone and Selegiline.	Depression [6A70-6A7Z]	[71]
Vortioxetine	DM6F1PU	Major	Additive serotonergic effects by the combination of Buspirone and Vortioxetine.	Depression [6A70-6A7Z]	[60]
Isocarboxazid	DMAF1NB	Major	Additive serotonergic effects by the combination of Buspirone and Isocarboxazid.	Depression [6A70-6A7Z]	[71]
Milnacipran	DMBFE74	Major	Additive serotonergic effects by the combination of Buspirone and Milnacipran.	Depression [6A70-6A7Z]	[60]
Escitalopram	DMFK9HG	Major	Additive serotonergic effects by the combination of Buspirone and Escitalopram.	Depression [6A70-6A7Z]	[60]
Tranylcypromine	DMGB5RE	Major	Additive serotonergic effects by the combination of Buspirone and Tranylcypromine.	Depression [6A70-6A7Z]	[71]
Desvenlafaxine	DMHD4PE	Major	Additive serotonergic effects by the combination of Buspirone and Desvenlafaxine.	Depression [6A70-6A7Z]	[60]
Phenelzine	DMHIDUE	Major	Additive serotonergic effects by the combination of Buspirone and Phenelzine.	Depression [6A70-6A7Z]	[71]
Clomipramine	DMINRKW	Major	Additive serotonergic effects by the combination of Buspirone and Clomipramine.	Depression [6A70-6A7Z]	[60]
Trazodone	DMK1GBJ	Major	Additive serotonergic effects by the combination of Buspirone and Trazodone.	Depression [6A70-6A7Z]	[60]
Amoxapine	DMKITQE	Major	Additive serotonergic effects by the combination of Buspirone and Amoxapine.	Depression [6A70-6A7Z]	[60]
Doxepin	DMPI98T	Major	Additive serotonergic effects by the combination of Buspirone and Doxepin.	Depression [6A70-6A7Z]	[60]
Maprotiline	DMPWB7T	Major	Additive serotonergic effects by the combination of Buspirone and Maprotiline.	Depression [6A70-6A7Z]	[60]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Buspirone and Esketamine.	Depression [6A70-6A7Z]	[58]
5-hydroxy-L-tryptophan	DMDWZGJ	Major	Additive serotonergic effects by the combination of Buspirone and 5-hydroxy-L-tryptophan.	Discovery agent [N.A.]	[72]
Fenfluramine	DM0762O	Major	Additive serotonergic effects by the combination of Buspirone and Fenfluramine.	Epilepsy/seizure [8A61-8A6Z]	[60]
Primidone	DM0WX6I	Major	Increased metabolism of Buspirone caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[55]
Felbamate	DM1V5ZS	Moderate	Increased metabolism of Buspirone caused by Felbamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[55]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Buspirone caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[55]
Cenobamate	DMGOVHA	Moderate	Increased metabolism of Buspirone caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[55]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Buspirone caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[73]
Fosphenytoin	DMOX3LB	Major	Increased metabolism of Buspirone caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[55]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Buspirone caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[55]
Phenobarbital	DMXZOCG	Major	Increased metabolism of Buspirone caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[55]
Carbamazepine	DMZOLBI	Major	Increased metabolism of Buspirone caused by Carbamazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[55]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Buspirone caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[55]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Buspirone caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[74]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Buspirone caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[59]
Ketoconazole	DMPZI3Q	Moderate	Decreased metabolism of Buspirone caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[59]
Sulfinpyrazone	DMEV954	Moderate	Increased metabolism of Buspirone caused by Sulfinpyrazone mediated induction of CYP450 enzyme.	Gout [FA25]	[55]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Buspirone caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[75]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Buspirone caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[76]
Rifampin	DMA8J1G	Major	Increased metabolism of Buspirone caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[55]
Rifapentine	DMCHV4I	Major	Increased metabolism of Buspirone caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[55]
Delavirdine	DM3NF5G	Minor	Decreased metabolism of Buspirone caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[77]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Buspirone caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[78]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Buspirone caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[79]
Efavirenz	DMC0GSJ	Moderate	Increased metabolism of Buspirone caused by Efavirenz mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[55]
Saquinavir	DMG814N	Moderate	Decreased metabolism of Buspirone caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[80]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Buspirone caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[81]
Amprenavir	DMLMXE0	Moderate	Decreased metabolism of Buspirone caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[78]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Buspirone caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[82]
Ritonavir	DMU764S	Moderate	Decreased metabolism of Buspirone caused by Ritonavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[83]
Conivaptan	DM1V329	Moderate	Decreased metabolism of Buspirone caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[84]
Lesinurad	DMUR64T	Moderate	Increased metabolism of Buspirone caused by Lesinurad mediated induction of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[55]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Buspirone caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[55]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Increased metabolism of Buspirone caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[55]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Buspirone caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[55]
Ceritinib	DMB920Z	Moderate	Decreased metabolism of Buspirone caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[85]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Buspirone caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[55]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Buspirone caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[85]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Buspirone caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[86]
Vemurafenib	DM62UG5	Moderate	Increased metabolism of Buspirone caused by Vemurafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[55]
LGX818	DMNQXV8	Moderate	Increased metabolism of Buspirone caused by LGX818 mediated induction of CYP450 enzyme.	Melanoma [2C30]	[87]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Buspirone caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[85]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Buspirone and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[88]
Exjade	DMHPRWG	Moderate	Increased metabolism of Buspirone caused by Exjade mediated induction of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[55]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Buspirone and Flibanserin.	Mood disorder [6A60-6E23]	[89]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Buspirone and Thalidomide.	Multiple myeloma [2A83]	[90]
Rifabutin	DM1YBHK	Major	Increased metabolism of Buspirone caused by Rifabutin mediated induction of CYP450 enzyme.	Mycobacterium infection [1B10-1B21]	[55]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Buspirone caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[91]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Buspirone caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[92]
Modafinil	DMYILBE	Moderate	Increased metabolism of Buspirone caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[55]
Granisetron	DMIUW25	Major	Additive serotonergic effects by the combination of Buspirone and Granisetron.	Nausea/vomiting [MD90]	[93]
Dolasetron	DMMG26Z	Major	Additive serotonergic effects by the combination of Buspirone and Dolasetron.	Nausea/vomiting [MD90]	[93]
Ondansetron	DMOTQ1I	Major	Additive serotonergic effects by the combination of Buspirone and Ondansetron.	Nausea/vomiting [MD90]	[93]
Entrectinib	DMMPTLH	Moderate	Decreased metabolism of Buspirone caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[94]
Sibutramine	DMFJTDI	Major	Additive serotonergic effects by the combination of Buspirone and Sibutramine.	Obesity [5B80-5B81]	[95]
Lorcaserin	DMG6OYJ	Major	Additive serotonergic effects by the combination of Buspirone and Lorcaserin.	Obesity [5B80-5B81]	[96]
Dexfenfluramine	DMJ7YDS	Major	Additive serotonergic effects by the combination of Buspirone and Dexfenfluramine.	Obesity [5B80-5B81]	[60]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Buspirone and Apraclonidine.	Optic nerve disorder [9C40]	[97]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Buspirone caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[98]
Pentazocine	DM1XBHS	Major	Additive CNS depression effects by the combination of Buspirone and Pentazocine.	Pain [MG30-MG3Z]	[57]
Dextropropoxyphene	DM23HCX	Major	Additive CNS depression effects by the combination of Buspirone and Dextropropoxyphene.	Pain [MG30-MG3Z]	[99]
Butorphanol	DM5KYPJ	Major	Additive CNS depression effects by the combination of Buspirone and Butorphanol.	Pain [MG30-MG3Z]	[57]
Oxymorphone	DM65AGJ	Major	Additive CNS depression effects by the combination of Buspirone and Oxymorphone.	Pain [MG30-MG3Z]	[57]
Levorphanol	DMGS80V	Major	Additive CNS depression effects by the combination of Buspirone and Levorphanol.	Pain [MG30-MG3Z]	[57]
Dezocine	DMJDB0Y	Major	Additive CNS depression effects by the combination of Buspirone and Dezocine.	Pain [MG30-MG3Z]	[57]
Nalbuphine	DMOSQGU	Major	Additive CNS depression effects by the combination of Buspirone and Nalbuphine.	Pain [MG30-MG3Z]	[57]
Buprenorphine	DMPRI8G	Major	Additive CNS depression effects by the combination of Buspirone and Buprenorphine.	Pain [MG30-MG3Z]	[100]
Safinamide	DM0YWJC	Major	Additive serotonergic effects by the combination of Buspirone and Safinamide.	Parkinsonism [8A00]	[71]
Rasagiline	DM3WKQ4	Major	Additive serotonergic effects by the combination of Buspirone and Rasagiline.	Parkinsonism [8A00]	[71]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Buspirone caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[101]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Buspirone caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[102]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Buspirone caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[103]
Enzalutamide	DMGL19D	Major	Increased metabolism of Buspirone caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[55]
Bosentan	DMIOGBU	Moderate	Increased metabolism of Buspirone caused by Bosentan mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[55]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Buspirone and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[104]
Dexamethasone	DMMWZET	Moderate	Increased metabolism of Buspirone caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[55]
Nafcillin	DMN9RPO	Moderate	Increased metabolism of Buspirone caused by Nafcillin mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[55]
Fentanyl	DM8WAHT	Major	Additive serotonergic effects by the combination of Buspirone and Fentanyl.	Sensation disturbance [MB40]	[67]
Sufentanil	DMU7YEL	Major	Additive serotonergic effects by the combination of Buspirone and Sufentanil.	Sensation disturbance [MB40]	[67]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Buspirone caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[105]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Buspirone caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[55]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Buspirone caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[58]
Armodafinil	DMGB035	Moderate	Increased metabolism of Buspirone caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[55]
LEE011	DMMX75K	Moderate	Decreased metabolism of Buspirone caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[106]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Buspirone caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[107]
Tizanidine	DMR2IQ4	Moderate	Additive CNS depression effects by the combination of Buspirone and Tizanidine.	Tonus and reflex abnormality [MB47]	[108]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Buspirone and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[104]
Tacrolimus	DMZ7XNQ	Moderate	Increased plasma concentrations of Buspirone and Tacrolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[104]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Buspirone caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[55]
-----------


⏷ Show the Full List of 135 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Eisenoxyd	E00585	56841934	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Water	E00035	962	Solvent
Hydrophobic colloidal silica	E00285	24261	Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent
--------------------


⏷ Show the Full List of 10 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Buspirone 10 mg tablet	10 mg	Oral Tablet	Oral
Buspirone 15 mg tablet	15 mg	Oral Tablet	Oral
Buspirone 30 mg tablet	30 mg	Oral Tablet	Oral
Buspirone 5 mg tablet	5 mg	Oral Tablet	Oral
Buspirone 7.5 mg tablet	7.5 mg	Oral Tablet	Oral
Buspirone Hydrochloride 5mg tablet	5mg	Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 36).
2	Glutamate and anxiety disorders. Curr Psychiatry Rep. 2007 Aug;9(4):278-83.
3	Seltzer B: Donepezil: a review. Expert Opin Drug Metab Toxicol. 2005 Oct;1(3):527-36. doi: 10.1517/17425255.1.3.527 .
4	BDDCS applied to over 900 drugs
5	Mahmood I, Sahajwalla C: Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. Clin Pharmacokinet. 1999 Apr;36(4):277-87. doi: 10.2165/00003088-199936040-00003.
6	BuSpar? (buspirone HCl) FDA Label
7	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8	Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204.
9	Effects of cytochrome P450 (CYP) 3A4 inhibitors on the anxiolytic action of tandospirone in rat contextual conditioned fear. Prog Neuropsychopharmacol Biol Psychiatry. 2007 May 9;31(4):926-31.
10	Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab Dispos. 2005 Apr;33(4):500-7.
11	Drug Interactions Flockhart Table
12	The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities. Trends Biotechnol. 2007 Jul;25(7):289-98.
13	acillus megaterium SF185 spores exert protective effects against oxidative stress in vivo and in vitro. Sci Rep. 2019 Aug 19;9(1):12082.
14	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
15	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
16	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
17	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
18	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
19	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
20	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
21	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
22	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
23	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
24	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
25	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
26	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
27	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
28	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
29	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
30	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
31	Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
32	Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
33	Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
34	Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
35	Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
36	Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
37	Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
38	Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
39	The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
40	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
41	Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
42	The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
43	Both reactivity and accessibility are important in cytochrome P450 metabolism: a combined DFT and MD study of fenamic acids in BM3 mutants. J Chem Inf Model. 2019 Feb 25;59(2):743-753.
44	Wild-type CYP102A1 as a biocatalyst: turnover of drugs usually metabolised by human liver enzymes. J Biol Inorg Chem. 2007 Mar;12(3):313-23.
45	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
46	Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
47	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
48	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
49	Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
50	Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
51	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
52	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
53	Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
54	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
55	Kivisto KT, Lamberg TS, Neuvonen PJ "Interactions of buspirone with itraconazole and rifampicin: Effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone." Pharmacol Toxicol 84 (1999): 94-7. [PMID: 10068153]
56	Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
57	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
58	Cerner Multum, Inc. "Australian Product Information.".
59	Kivisto KT, Lamberg TS, Kantola T, Neuvonen PJ "Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole." Clin Pharmacol Ther 62 (1997): 348-54. [PMID: 9333111]
60	Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
61	Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61. [PMID: 15827071]
62	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
63	Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
64	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
65	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
66	Gill SS, Wright EM, Reilly CS "Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study." Br J Anaesth 65 (1990): 760-5. [PMID: 2265045]
67	Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
68	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
69	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
70	Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
71	Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
72	Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50. [PMID: 1968472]
73	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
74	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
75	Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
76	Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
77	Barry M, Mulcahy F, Merry C, Gibbons S, Back D "Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection." Clin Pharmacokinet 36 (1999): 289-304. [PMID: 10320951]
78	Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
79	Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
80	Product Information. Fortovase (saquinavir) Roche Laboratories, Nutley, NJ.
81	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
82	Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
83	Clay PG, Adams MM "Pseudo-Parkinson disease secondary to ritonavir-buspirone interaction." Ann Pharmacother 37 (2003): 202-5. [PMID: 12549947]
84	Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
85	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
86	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
87	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
88	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
89	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
90	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
91	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
92	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
93	Canadian Pharmacists Association.
94	Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
95	Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
96	Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
97	Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
98	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
99	Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
100	Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
101	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
102	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
103	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
104	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
105	Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
106	DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
107	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
108	Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.